For immediate release |
17 October 2013 |
Futura Medical plc
("Futura" or the "Company")
Award of CE Mark Certificate
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce the award of the CE mark certificate for CSD500, the Company's novel condom.
CSD500 is clinically proven to produce a firmer erection and increase penile size in healthy men whilst wearing a condom during sexual intercourse and to give women a longer lasting sexual experience.
The award of the CE mark means that CSD500 can be marketed in all European territories and also in a number of non-European territories that recognise the CE mark process.
Steven Cugine, Church & Dwight's President of International Consumer Products, commented: "We congratulate Futura on gaining regulatory approval in Europe for CSD500 and we look forward to continuing to work with Futura towards the launch of this extremely novel condom."
James Barder, Futura's Chief Executive, commented: "We are delighted to receive the CE mark certificate for CSD500. This means that the product is now approved for marketing throughout Europe, where it has already been licensed to Church & Dwight, owner of the highly trusted Trojan brand, in certain key territories. Discussions are proceeding well with potential licensing partners for other territories within Europe, and also for other territories worldwide."
For any further information please contact:
Futura Medical plc |
|
James Barder, Chief Executive |
Tel: +44 (0)1483 685 670 |
mail to: [email protected] |
www.futuramedical.com |
|
|
Cenkos Securities plc |
|
Bobbie Hilliam |
Tel:+44 (0)20 7397 8900 |
|
|
For media enquiries please contact: |
|
|
|
Buchanan |
|
Mark Court / Fiona Henson / Sophie Cowles www.buchanan.uk.com |
Tel: +44 (0)20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com
